Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 200M | 15.9% |
Gross Profit | 72M | 105.1% |
Cost of Revenue | 128M | 6.8% |
Operating expense | 229M | 2.3% |
Net Income | -38M | 43.3% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 904M | 8.7% |
Total Liabilities | 640M | 13.3% |
Total Equity | 264M | 0.9% |
Shares Outstanding | 122M | 0.3% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -8.3M | 93.7% |
Cash from investing | -90,000 | 69.3% |
Cash from financing | 42M | 60.7% |
EPS
Financial Highlights for Apellis Pharmaceuticals in Q2 '24
Apellis Pharmaceuticals reported a revenue of 200M, which is a 15.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 72M, marking a 105.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 128M, a -6.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 229M, showing a -2.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -38M, showing a 43.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Apellis Pharmaceuticals with growth in revenue, gross profit, and net income.